Forte Biosciences, Inc. (FBRX)

Forte Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	76.96	22.24	37.13	41.1	42.04
Short-Term Investments	-	36.12	-	-	-
Cash & Short-Term Investments	76.96	58.37	37.13	41.1	42.04
Cash Growth	31.86%	57.21%	-9.67%	-2.25%	-28.45%
Other Current Assets	3.63	2.98	1.2	0.41	0.48
Total Current Assets	80.59	61.35	38.33	41.51	42.52
Net Property, Plant & Equipment	0.13	0.08	0.11	-	-
Other Long-Term Assets	2.06	0.14	0.54	0.49	0.79
Total Assets	82.78	61.56	38.98	42	43.31
Accounts Payable	9.99	4.88	1.42	1.15	0.95
Accrued Expenses	11.8	4.2	2.24	2.03	0.81
Total Current Liabilities	20.75	9.08	3.67	3.18	1.76
Total Liabilities	21.79	9.08	3.67	3.18	1.76
Shareholders' Equity	60.99	52.48	35.31	38.82	41.55
Total Liabilities & Equity	82.78	61.56	38.98	42	43.31
Net Cash (Debt)	76.96	58.37	37.13	41.1	42.04
Net Cash Growth	31.86%	57.21%	-9.67%	-2.25%	-28.45%
Net Cash Per Share	5.23	20.02	29.40	59.11	75.25
Book Value	60.99	52.48	35.31	38.82	41.55
Book Value Per Share	4.14	18.00	27.96	55.83	74.36
Tangible Book Value	60.99	52.48	35.31	38.82	41.55
Tangible Book Value Per Share	4.14	18.00	27.96	55.83	74.36

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q